These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 16810617)

  • 41. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
    Tefferi A; Vainchenker W
    J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
    Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
    Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Randi ML; Fabris F; Girolami A
    Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
    Najean Y
    Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
    Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 55. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 56. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 59. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC
    Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.